Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est
Fulgent Genetics Raises FY24 Adj EPS Guidance From $(0.30) to $0.33 Vs $(0.39) Est; Affirms Sales Guidance Of $280.00M Vs $282.16M Est
Fulgent Genetics將FY24調整後的每股收益指引從（0.30美元）提高至0.33美元，預估爲（0.39美元）; 確認銷售指引爲28000萬美元，預估爲28216萬美元
Outlook:
展望：
For the full year 2024, Fulgent expects:
對於2024年全年，Fulgent預計：
- Core Revenue of approximately $280 million
- GAAP loss improvement from approximately ($1.95) per share to approximately ($1.70) per share
- Non-GAAP loss improvement from approximately ($0.30) loss per share to approximately $0.33 income per share
- Cash, cash equivalents, and investments in marketable securities of approximately $800 million as of December 31, 2024*
- 核心營業收入約爲$28000萬
- 按照通用會計準則（GAAP），每股虧損從約（$1.95）改善爲約（$1.70）
- 非通用會計準則（Non-GAAP）每股虧損從約（$0.30）改善爲約$0.33每股收入
- 截至2024年12月31日，現金、現金等價物和可市場化證券的投資約爲$80000萬*
*Cash expenditures may be higher or lower than currently estimated due to a variety of factors and circumstances, including as a result of the Company's ongoing stock repurchase program or other expenditures outside the ordinary course of business.
*現金支出可能會因多種因素和情況而高於或低於目前的估計，包括由於公司持續的股票回購計劃或其他非正常業務支出。
資訊熱榜
更新時間